argenx SE (BVMF:A1RG34)

Brazil flag Brazil · Delayed Price · Currency is BRL
189.26
0.00 (0.00%)
At close: Dec 19, 2025
22.62%
Market Cap285.90B
Revenue (ttm)19.63B
Net Income (ttm)8.17B
Shares Outn/a
EPS (ttm)124.02
PE Ratio34.99
Forward PE28.67
Dividendn/a
Ex-Dividend Daten/a
Volume380
Average Volume246
Open189.38
Previous Closen/a
Day's Range189.26 - 189.38
52-Week Range116.88 - 200.20
Beta-0.11
RSI57.97
Earnings DateMar 5, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1RG34
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.